European Stock Today

EBAC -  USA Stock  

USD 9.82  0.10  1.03%

European Biotech is trading at 9.82 as of the 20th of October 2021, a 1.03 percent up since the beginning of the trading day. The stock's open price was 9.72. European Biotech has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for European Biotech Acquisition are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 21st of August 2021 and ending today, the 20th of October 2021. Click here to learn more.
 Market Performance
0 of 100
  Odds Of Distress
Over 76
European Biotech Acquisition Corp. does not have significant operations. The company was incorporated in 2021 and is based in Amsterdam, the Netherlands. European Biotech is traded on NASDAQ Exchange in the United States.. The company has 13.21 M outstanding shares of which 125 shares are currently shorted by private and institutional investors with about 0.24 trading days to cover. More on European Biotech Acquisition
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

European Biotech Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. European Biotech's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding European Biotech or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
European Biotech Acq has high likelihood to experience some financial distress in the next 2 years
Legal NameEuropean Biotech Acquisition
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of European Biotech's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
European Biotech Acquisition (EBAC) is traded on NASDAQ Exchange in USA . The company currently falls under 'Small-Cap' category with current market capitalization of 163.6 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate European Biotech's market, we take the total number of its shares issued and multiply it by European Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. European Biotech Acq conducts business under Financial Services sector and is part of Shell Companies industry. The entity has 13.21 M outstanding shares of which 125 shares are currently shorted by private and institutional investors with about 0.24 trading days to cover.
Check European Biotech Probability Of Bankruptcy
Ownership
European Biotech Acq retains a total of 13.21 Million outstanding shares. 30% of European Biotech Acquisition outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulation than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or about to change. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.

Ownership Allocation (%)

Check European Ownership Details

European Stock Price Odds Analysis

What are European Biotech's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of European Biotech jumping above the current price in 90 days from now is about 1.1%. The European Biotech Acquisition probability density function shows the probability of European Biotech stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days European Biotech has a beta of 0.0068 suggesting as returns on the market go up, European Biotech average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding European Biotech Acquisition will be expected to be much smaller as well. Additionally, the company has an alpha of 0.0163, implying that it can generate a 0.0163 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Odds Down 9.82HorizonTargetOdds Up 9.82 
98.76%90 days
 9.82 
1.10%
Based on a normal probability distribution, the odds of European Biotech to move above the current price in 90 days from now is about 1.1 (This European Biotech Acquisition probability density function shows the probability of European Stock to fall within a particular range of prices over 90 days) .

European Stock Institutional Holders

Institutional Holdings refers to the ownership stake in European Biotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of European Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing European Biotech's value.
InstituionSecurity TypeTotal SharesValue
Millennium Management LlcCommon Shares856.6 K8.5 M
Citadel Advisors LlcCommon Shares625.3 KM
View European Biotech Diagnostics

European Biotech Acq Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. European Biotech market risk premium is the additional return an investor will receive from holding European Biotech long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in European Biotech. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although European Biotech's alpha and beta are two of the key measurements used to evaluate European Biotech's performance over the market, the standard measures of volatility play an important role as well.

European Stock Against Markets

Picking the right benchmark for European Biotech stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in European Biotech stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for European Biotech is critical whether you are bullish or bearish towards European Biotech Acquisition at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in European Biotech without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Performance Analysis Now

   

Performance Analysis

Check effects of mean-variance optimization against your current asset allocation
All  Next Launch Module
Continue to Investing Opportunities. Note that the European Biotech Acq information on this page should be used as a complementary analysis to other European Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try ETF Directory module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for European Stock analysis

When running European Biotech Acq price analysis, check to measure European Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy European Biotech is operating at the current time. Most of European Biotech's value examination focuses on studying past and present price action to predict the probability of European Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move European Biotech's price. Additionally, you may evaluate how the addition of European Biotech to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
The market value of European Biotech Acq is measured differently than its book value, which is the value of European that is recorded on the company's balance sheet. Investors also form their own opinion of European Biotech's value that differs from its market value or its book value, called intrinsic value, which is European Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because European Biotech's market value can be influenced by many factors that don't directly affect European Biotech Acq underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between European Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine European Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, European Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.